Treatment of Mood Disorders in Multiple Sclerosis

Current Treatment Options in Neurology

Volumn 17, Issue 1, 2015, Pages 1-11

  Pérez, Luis Pintor ^a,c   González, Roberto Sánchez ^b   Lázaro, Eva Baillés ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Institut de Neuropsiquiatria i Addiccions   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Antidepressant; Depression; Mood disorders; Multiple sclerosis; Neurology; Pharmacotherapy; Psychiatry; Psychotherapy

Indexed keywords

BETA1A INTERFERON; DULOXETINE; FLUVOXAMINE; INTERFERON BETA SERINE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TERIFLUNOMIDE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADJUSTMENT DISORDER; COGNITIVE THERAPY; COMORBIDITY; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; HUMAN; MAJOR DEPRESSION; MINDFULNESS; MOOD DISORDER; MULTIPLE SCLEROSIS; PRACTICE GUIDELINE; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 84911938897     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-014-0323-4     Document Type: Review

References (34)

1. Goldman Consensus Group. The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler. 2005;11(3):328–37. This article summarizes epidemiological, clinical, neurobiological, diagnostic and therapeutic aspects of depression in MS.
2. Minden SL, Feinstein A, Kalb RC, et al. Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(2):174–81. This article is a up-to-date review of evidence-based recommendations for screening, diagnosing and treating psychiatric disorders in MS.
3. Marrie RA, Horwitz R, Cutter G, et al. The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated. Mult Scler. 2009;15(3):385–92.
4. Patten SB, Beck CA, Williams JV, et al. Major depression in multiple sclerosis: a population-based perspective. Neurology. 2003;61(11):1524–7.
5. American Psychiatric Association. Diagnostic and Statistical Manual of mental disorders, fifth edition – DSM-5. Arlington: American Psychiatric Publishing; 2013.
6. Feinstein A. Multiple sclerosis and depression. Mult Scler. 2011;17(11):1276–81.
7. Skokou M, Soubasi E, Gourzis P. Depression in multiple sclerosis: a review of assessment and treatment approaches in adult and pediatric populations. ISRN Neurol. 2012;2012:427102.
8. Rosen HJ, Cummings J. A real reason for patients with pseudobulbar affect to smile. Ann Neurol. 2007;61(2):92–6.
9. Paparrigopoulos T, Ferentinos P, Kouzoupis A, et al. The neuropsychiatry of multiple sclerosis: focus on disorders of mood, affect and behaviour. Int Rev Psychiatry. 2010;22(1):14–21.
10. Siegert RJ, Abernethy DA. Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry. 2005;76:469–75.
11. Raskind MA. Diagnosis and treatment of depression comorbid with neurologic disorders. Am J Med. 2008;121(11 Suppl2):S28–37.
12. Stahl SM. Stahl’s essential psychopharmacology: the prescriber’s guide. Antidepressants. New York: Cambridge University Press; 2011.
13. Ramsberg J, Asseburg C, Henriksson M. Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model. PLoS One. 2012;7(8):e42003.
14. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746–58.
15. Ehde DM, Kraft GH, Chwastiak L, et al. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. Gen Hosp Psychiatry. 2008;30(1):40–8.
16. Koch MW, Glazenborg A, Uyttenboogaart M. Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database Syst Rev. 2011;2, CD007295.
17. Scott TF, Nussbaum P, McConnell H, et al. Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carroll scale. Neurol Res. 1995;17(6):421–2.
18. Mohr DC, Boudewyn AC, Goodkin DE, et al. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol. 2001;69(6):942–9.
19. Benedetti F, Campori E, Colombo C, et al. Fluvoxamine treatment of major depression associated with multiple sclerosis. J Neuropsychiatry Clin Neurosci. 2004;16(3):364–6.
20. Solaro C, Bergamaschi R, Rezzani C, et al. Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study. Clin Neuropharmacol. 2013;36(4):114–6.
21. Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry. 1990;147(11):1493–7.
22. Barak Y, Ur E, Achiron A. Moclobemide treatment in multiple sclerosis patients with comorbid depression: an open-label safety trial. J Neuropsychiatry Clin Neurosci. 1999;11(2):271–3.
23. Mattingly G, Baker K, Zorumski CF. Multiple sclerosis and ECT: possible value of gadolinium-enhanced magnetic resonance scans for identifying high-risk patients. J Neuropsychiatry Clin Neurosci. 1992;4(2):145–51.
24. Rasmussen KG, Keegan BM. Electroconvulsive therapy in patients with multiple sclerosis. J ECT. 2007;23(3):179–80.
25. Pontikes TK, Dinwiddie SH. Electroconvulsive therapy in a patient with multiple sclerosis and recurrent catatonia. J ECT. 2010;26(4):270–1.
26. Urban-Kowalczyk M, Rudecki T, Wróblewski D, et al. Electroconvulsive therapy in patient with psychotic depression and multiple sclerosis. Neurocase. 2014;20(4):452–5.
27. Hind D, Cotter J, Thake A, Bradburn M, Cooper C, Isaac C, et al. Cognitive behavioural therapy for the treatment of depression in people with multiple sclerosis: a systematic review and meta-analysis. BMC Psychiatry. 2014;14:5. This article is a up-to-date review of evidence-based recommendations for CBT in depressive disorders in MS.
28. Forman AC, Lincoln NB. Evaluation of an adjustment group for people with multiple sclerosis: a pilot randomized controlled trial. Clin Rehabil. 2010;24:211–21.
29. Lincoln NB, Yuill F, Holmes J, Drummond AE, Constantinescu CS, Armstrong S, et al. Evaluation of an adjustment group for people with multiple sclerosis and low mood: a randomized controlled trial. Mult Scler. 2011;17:1250–7.
30. Mohr DC, Hart SL, Julian L, et al. Telephone-administered psychotherapy for depression. Arch Gen Psychiatry. 2005;62(9):1007–14.
31. Cooper CL, Hind D, Parry GD, Isaac CL, Dimairo M, O’Cathain A, et al. Computerised cognitive behavioural therapy for the treatment of depression in people with multiple sclerosis: external pilot trial. Trials. 2011;12:259.
32. Simpson R, Booth J, Lawrence M, Byrne S, Mair F, Mercer S. Mindfulness based interventions in multiple sclerosis - a systematic review. BMC Neurol. 2014;14:15.
33. Mills N, Allen J. Mindfulness of movement as a coping strategy in multiple sclerosis: a pilot study. Gen Hosp Psychiatry. 2000;22(6):425–31.
34. Grossman P, Kappos L, Gensicke H, D’Souza M, Mohr DC, Penner IK, et al. MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology. 2010;75(13):1141–9.